Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02153229 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma
A Phase 2 study of Epitheliod Malignant Pleural Mesothelioma, sponsored by Abramson Cancer Center at Penn Medicine.
- Active
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
- 2
- Study locations
NCT02153229 is a Phase 2 study of Epitheliod Malignant Pleural Mesothelioma that is active but no longer recruiting, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 52 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT02153229, a Phase 2 study of Epitheliod Malignant Pleural Mesothelioma, is active but no longer recruiting, sponsored by Abramson Cancer Center at Penn Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
- 2
- Study locations
Study Summary
A randomized Phase II trial to test whether the addition of intraoperative Photofrin-mediated photodynamic therapy to radical pleurectomy and post-operative chemo.improves OS in the treatment of patients with epithelioid MPM. Subjects assigned to the PDT arm will be given the photosensitizer prior to surgery . All subjects will receive maximal surgical debulking. Subjects in the PDT arm will receive intraoperative treatment using real-time, isotropic light dosimetry.
Conditions Studied
Interventions
- RADIATION Photodynamic Therapy
- PROCEDURE Radical Pleurectomy
- RADIATION Chemotherapy
- DRUG Photofrin 2.0 mg/kg
Study Locations (2)
New York
- Roswell Park Cancer Institute - Buffalo
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2014-06-02 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02153229
The ClinicalTrials.gov registry entry for NCT02153229 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Epitheliod Malignant Pleural Mesothelioma appearing as the primary indexed condition, and to 4 interventions - of which Photodynamic Therapy is the first listed.
NCT02153229 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New York, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02153229 about?
NCT02153229 is a clinical study titled "Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma". A randomized Phase II trial to test whether the addition of intraoperative Photofrin-mediated photodynamic therapy to radical pleurectomy and post-operative chemo.improves OS in the treatment of patients with epithelioid MPM. Subjects assigned to the PDT arm will be given the photosensitizer prior t...
What is the current status of trial NCT02153229?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2014-06-02. Estimated completion is 2027-12.
What conditions does trial NCT02153229 study?
This clinical trial studies the following conditions: Epitheliod Malignant Pleural Mesothelioma.
What interventions are being tested in trial NCT02153229?
The interventions under investigation include: Photodynamic Therapy (RADIATION), Radical Pleurectomy (PROCEDURE), Chemotherapy (RADIATION), Photofrin 2.0 mg/kg (DRUG).
Who is sponsoring clinical trial NCT02153229?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02153229 being conducted?
This trial has 2 study locations across New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.